Literature DB >> 12069841

Stereochemical properties of lysophosphatidic acid receptor activation and metabolism.

Kazuaki Yokoyama1, Daniel L Baker, Tamas Virag, Karoly Liliom, Hoe Sup Byun, Gabor Tigyi, Robert Bittman.   

Abstract

Ligand recognition by G protein-coupled receptors (GPCR), as well as substrate recognition by enzymes, almost always shows a preference for a naturally occurring enantiomer over the unnatural one. Recognition of lysophosphatidic acid (LPA) by its receptors is an exception, as both the natural L (R) and unnatural D (S) stereoisomers of LPA are equally active in bioassays. In contrast to the enantiomers of LPA, analogs of N-acyl-serine phosphoric acid (NASPA) and N-acyl-ethanolamine phosphoric acid (NAEPA), which contain a serine and an ethanolamine backbone, respectively, in place of glycerol, are recognized in a stereoselective manner. This stereoselective interaction may lead to the development of receptor subtype-selective antagonists. In the present study, we review the stereochemical aspects of LPA pharmacology and describe the chemical synthesis of pure LPA enantiomers together with their ligand-binding properties toward the LPA1, LPA2, and LPA3 receptors and their metabolism by lipid phosphate phosphatase 1 (LPP1). Finally, we evaluate the concept of stereopharmacology in developing novel ligands for LPA receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069841     DOI: 10.1016/s1388-1981(02)00184-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid.

Authors:  Renuka Gupte; Anjaih Siddam; Yan Lu; Wei Li; Yuko Fujiwara; Nattapon Panupinthu; Truc-Chi Pham; Daniel L Baker; Abby L Parrill; Mari Gotoh; Kimiko Murakami-Murofushi; Susumu Kobayashi; Gordon B Mills; Gabor Tigyi; Duane D Miller
Journal:  Bioorg Med Chem Lett       Date:  2010-10-08       Impact factor: 2.823

2.  Cannabinoid receptor agonists potentiate action potential-independent release of GABA in the dentate gyrus through a CB1 receptor-independent mechanism.

Authors:  Mackenzie E Hofmann; Chinki Bhatia; Charles J Frazier
Journal:  J Physiol       Date:  2011-06-06       Impact factor: 5.182

3.  Synthesis of photoactivatable analogues of lysophosphatidic acid and covalent labeling of plasma proteins.

Authors:  Zaiguo Li; Daniel L Baker; Gabor Tigyi; Robert Bittman
Journal:  J Org Chem       Date:  2006-01-20       Impact factor: 4.354

4.  Lack of stereospecificity in lysophosphatidic acid enantiomer-induced calcium mobilization in human erythroleukemia cells.

Authors:  Ulrika K Nilsson; Rolf G G Andersson; Johan Ekeroth; Elisabeth C Hallin; Peter Konradsson; Jan Lindberg; Samuel P S Svensson
Journal:  Lipids       Date:  2003-10       Impact factor: 1.880

5.  Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.

Authors:  Yunhui Cheng; Natalia Makarova; Ryoko Tsukahara; Huazhang Guo; E Shuyu; Patricia Farrar; Louisa Balazs; Chunxiang Zhang; Gabor Tigyi
Journal:  Cell Signal       Date:  2009-08-23       Impact factor: 4.315

Review 6.  Lysophospholipid interactions with protein targets.

Authors:  Abby L Parrill
Journal:  Biochim Biophys Acta       Date:  2008-05-02

7.  Lysophospholipid signaling: beyond the EDGs.

Authors:  William J Valentine; Yuko Fujiwara; Ryoko Tsukahara; Gabor Tigyi
Journal:  Biochim Biophys Acta       Date:  2007-08-25

8.  Lysophosphatidic acid induces neointima formation through PPARgamma activation.

Authors:  Chunxiang Zhang; Daniel L Baker; Satoshi Yasuda; Natalia Makarova; Louisa Balazs; Leonard R Johnson; Gopal K Marathe; Thomas M McIntyre; Yong Xu; Glenn D Prestwich; Hoe-Sup Byun; Robert Bittman; Gabor Tigyi
Journal:  J Exp Med       Date:  2004-03-08       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.